At Home | What's New | Financials | In the Clinic | Governance | R&D

Patent Estate

The Company has sought to establish a strong proprietary position. As of December 31, 2005, the Company had pending 3 original and continuation-in-part United States patent applications and numerous foreign counterparts. The Company has received or has exclusive rights to 187 issued U.S. and foreign patents.

AutoImmune has been granted:

Eight U.S. patents covering the use of oral Type I, II, or III collagen (or fragments of collagen) to treat rheumatoid arthritis;

Five U.S. patents covering treatment of cell-mediated autoimmune disease by nasal or by inhalation administration of autoantigens;

Two U.S. patents covering suppression of allograft rejection by oral administration of major histocompatibility complex class II antigens or an active fragment there of;

Five U.S. patents covering treatment, or prevention of the onset of, Type I diabetes by oral or nasal administration of insulin or its fragments;

One U.S. patent covering the treatment of uveoretinitis using oral S-antigen;

One U.S. patent covering the combination of oral tolerance and methotrexate in the treatment of multiple sclerosis;

Four U.S. patents directed to peptide fragments of myelin basic protein and the use of such fragments in suppressing proliferation of T cells activated in multiple sclerosis patients;

Three U.S. patent covering treatment of multiple sclerosis by oral administration of MBP or bovine myelin;

One U.S. patent covering a method of preparing Type II collagen; and

One U.S. patent covering suppression of vascular disorders by mucosal administration of heat shock protein.

Click on the colored bars at the top or on the following text to go to: OT Technology